Xtant Medical entered into a private label distribution agreement with curasan to distribute Matriform synthetic scaffolds in North America.
Matriform, comprising Beta-Tricalcium Phosphate and porcine collagen, allows Xtant to enter the bone graft substitute market. The company’s biologic lineup already includes demineralized bone matrix, allografts and a placental tissue matrix.
Matriform will be offered in flexible strip and moldable formats. The formulas received FDA 510(k) clearance at the end of 2016 (under the name CERASORB Ortho Foam), and have been used in Europe for >20 years.
Xtant Medical entered into a private label distribution agreement with curasan to distribute Matriform synthetic scaffolds in North America.
Matriform, comprising Beta-Tricalcium Phosphate and porcine collagen, allows Xtant to enter the bone graft substitute market. The company's biologic lineup already includes demineralized bone...
Xtant Medical entered into a private label distribution agreement with curasan to distribute Matriform synthetic scaffolds in North America.
Matriform, comprising Beta-Tricalcium Phosphate and porcine collagen, allows Xtant to enter the bone graft substitute market. The company’s biologic lineup already includes demineralized bone matrix, allografts and a placental tissue matrix.
Matriform will be offered in flexible strip and moldable formats. The formulas received FDA 510(k) clearance at the end of 2016 (under the name CERASORB Ortho Foam), and have been used in Europe for >20 years.
Copy to clipboard 
